In clinical practice, the expression of the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) identifies three main subgroups: Luminal or hormone receptor positive (HR-positive) BC, HER2-positive BC, and triple negative breast cancer (TNBC) [4]. Here, NR4A1 is linked to breast cancer.